MedTrace Logo

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

NCT00891345 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2012-04-27

No results posted yet for this study

Summary

This study is a phase I study of a new cell based prostate cancer therapy (ALECSAT). In this therapy specific cells from the patient's own immune system are isolated, activated and re-administered to the patient to boost a specific immune response against the cancer cells. The aim of the study is to show safety and tolerability for this type of therapy. It is the hypothesis that the cells administered during the therapy will attack the tumour cells and in this way stop or slow down the progression of disease.

Conditions

  • Hormone-refractory Prostate Cancer

Interventions

BIOLOGICAL

ALECSAT

Autologous activated CTL and NK-cells injected as a single intravenous injection.

Sponsors & Collaborators

  • CytoVac A/S

    lead INDUSTRY

Principal Investigators

  • Hans-Henrik Meyhoff, MD · Urologisk Klinik, Frederikssund Hospital, Frederikssundsvej 30, 3600 Frederikssund

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891345 on ClinicalTrials.gov